Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.59 |
| ▸ | SI | P14410 | 1/20 | 0.59 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11851530 | 0.98 | GAA (0.56) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL13756031 | 0.98 | GAA (0.56) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL8851605 | 0.93 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL20937509 | 0.93 | LTA4H (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL19102485 | 0.93 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL20937053 | 0.91 | LTA4H (0.54) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL1327984 | 0.91 | CYP1A2 (0.55) | GAAMGAMSIMGAM2CYP1A2 | |
| Hydrochloric Acid SCHEMBL1274072 | 0.91 | LTA4H (0.54) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL5701946 | 0.91 | GAA (0.50) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL11185820 | 0.91 | GAA (0.50) | GAAMGAMSIMGAM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117303816-A | Preparation method and application of collapsible loess curing agent | 宁夏路广通公路工程试验检测有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117247536-B | Perfluoropolyether aminosilane compound, composition, preparation method and application thereof | 松井新材料集团股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-113856637-B | Preparation method and application of chelate adsorption filler | 万华化学集团股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117303816-A | Preparation method and application of collapsible loess curing agent | 宁夏路广通公路工程试验检测有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117247536-A | Perfluoropolyether aminosilane compound, composition, preparation method and application thereof | 湖南松井新材料股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11256174-B2 | Pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-02-22 | — | — | US | disclosed |
| CN-113856637-A | Preparation method and application of chelate adsorption filler | 万华化学集团股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113527101-A | Novel compound, polymer and method for producing same, photosensitive resin composition, method for forming pattern, cured film, and electronic component | 信越化学工业株式会社 | 2021-10-22 | — | — | CN | disclosed |
| CN-113527680-A | Polymer, photosensitive resin composition, pattern forming method, cured film, and electronic component | 信越化学工业株式会社 | 2021-10-22 | — | — | CN | disclosed |
| US-10654032-B2 | Recyclable catalysts for chlorination of organic acids and alcohols | GALAXY SURFACTANTS LTD. (IN) | 2020-05-19 | — | — | US | disclosed |
| EP-1716156-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075484-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
| EP-1042279-B1 | SUBSTITUTED BETA-ALANINES | AVENTIS PHARMA LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-6352977-B1 | ALANINE WITH PRODRUGS | AVENTIS PHARMA LIMITED (GB) | 2002-03-05 | — | — | US | disclosed |
| EP-1042279-A1 | SUBSTITUTED BETA-ALANINES | Aventis Pharma Limited (GB) | 2000-10-11 | — | — | EP | disclosed |
| JP-2000143610-A | N-TERTIARY-BUTOXYCARBONYL-3,3'-IMINODIPROPIONATE, ITS PRODUCTION, AND PRODUCTION OF 1-TERTIARY- BUTOXYCARBONYL-4-OXO-3-PIPERIDINECARBOXYLATE | KOEI CHEM CO LTD | 2000-05-26 | — | — | JP | disclosed |
| WO-1999033789-A1 | SUBSTITUTED β-ALANINES | AVENTIS PHARMA LIMITED (GB) | 1999-07-08 | — | — | WO | disclosed |
| EP-0474323-A1 | Reducing chelants, their complexes with technetium and rhenium, method for their preparation and their use in diagnosis and therapy | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH, c/o FU KLINIKUM RUDOLF VIRCHOW (DE) | 1992-03-11 | — | — | EP | disclosed |
| US-4413005-A | 2,3-DIHYDRO-2,2-DIMETHYLBENZOFURAN-7-YL DERIVATIVES | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1983-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654032-B2 | Recyclable catalysts for chlorination of organic acids and alcohols | ADH1C, ADH1A, OTC | GAA 4321/4885MGAM 632/4885SI 2827/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | GAA 3297/4885MGAM 4818/4885SI 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.